2 Firms Will Lead Investor Suit Over GW Pharma's $7.2B Deal

By Katryna Perera (January 19, 2022, 5:57 PM EST) -- A California federal judge has appointed Monteverde & Associates and Kahn Swick & Foti as co-lead counsel of a proposed securities class action against GW Pharmaceuticals over claims that it misled investors to achieve a $7.2 billion acquisition deal with Ireland-based Jazz Pharmaceuticals.

Judge Cynthia Bashant of the U.S. District Court for the Southern District of California appointed the firms on Tuesday after receiving a request from them in August. She also appointed Kurt Ziegler and Daniel Brady as co-lead plaintiffs.

U.K.-based GW Pharmaceuticals makes cannabinoid-based treatments for rare diseases, including Epidiolex, the first drug derived from marijuana approved by the U.S. Food...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!